EVs derived from mesothelin (MSLN)-targeted chimeric antigen receptor T cells (CAR-T) cells have demonstrated efficacy in targeting MSLN-positive and triple-negative breast cancer cells. Here, MSLN is linked to triple-negative breast carcinoma.